AstraZeneca (AZN) has released an update.
AstraZeneca PLC reported strong financial performance for the first quarter of 2024, with a 19% increase in Total Revenue reaching $12,679 million, and a 13% rise in Core EPS to $2.06. The growth was driven by an 18% surge in Product Sales and significant progress in its Oncology, CVRM, R&I, and Rare Disease therapy areas. The company confirmed its annual dividend would rise by $0.20 to $3.10 per share and reiterated its full-year guidance, expecting a low double-digit to low teens percentage increase in both Total Revenue and Core EPS.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
